Combined Use of Nicotine Patch and Gum in Smoking Cessation: A Placebo-Controlled Clinical Trial

Kornitzer, Marcel; Boutsen, Michel; Dramaix, Michèle; Thijs, J. C.; Gustavsson, G

doi:10.1006/pmed.1995.1006

Cited by 216 publications

(103 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, smoking cessation programs may benefit from including or adding additional counseling or support related to ways to improve mood and deal with stressors without smoking during the second week after a quit attempt. Unlike prior studies of longer term relapse (Blondal, Gudmundsson, Olafsdottir, Gustavsson, & Westin, 1999;Bohadana, Nilsson, Rasmussen, & Martinet, 2000;Kornitzer, Boutsen, Dramaix, Thijs, & Gustavsson, 1995;Piper et al, 2009;Smith et al, 2009), the two treatment groups did not differ significantly from each other. Thus, although this study provides some evidence for the impact of treatment over placebo, it does not provide strong evidence for choosing one type of therapy over another.…”

Section: Discussioncontrasting

confidence: 91%

Time-Varying Processes Involved in Smoking Lapse in a Randomized Trial of Smoking Cessation Therapies

Vasilenko

Piper

Lanza

et al. 2014

Nicotine & Tobacco Research

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 91%

Time-Varying Processes Involved in Smoking Lapse in a Randomized Trial of Smoking Cessation Therapies

Vasilenko

Piper

Lanza

et al. 2014

Nicotine & Tobacco Research

View full text Add to dashboard Cite

show abstract

“…Although the point estimate favoured nicotine inhalers over placebo (odds ratio 2.17), these results were not conclusive because the 95% credible interval included unity (95% CrI 0. 59 15/44 9/43 Fiore et al 57 13/56 9/56 Glavas et al 58 10/57 4/55 Fiore et al 57 17/60 5/60 Paoletti et al 56 16/78 2/80 Westman et al 55 22/100 12/99 Abelin et al 53,54 21/103 15/104 Killen et al 52 15/109 11/108 Killen et al 52 28/113 10/107 Sachs et al 51 19/150 10/75 Kornitzer et al 50 33/120 17/120 Hurt et al 49 16/119 6/160 Hughes et al 46 16/154 3/144 Tonnesen et al 48 29/154 14/153 Richmond et al 47 4/160 6/160 Hughes et al 46 12/160 6/160 Hughes et al 46 27/184 16/185 Daughton et al 45 24/244 9/160 Jorenby et al 13 analysis, we found that all 7 pharmacotherapies were more efficacious than placebo ( Figure 6). …”

Section: Efficacy Of Smoking Cessation Pharmacotherapiesmentioning

confidence: 99%

Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials

Eisenberg¹,

Filion²,

Yavin³

et al. 2008

Canadian Medical Association Journal

271

181

View full text Add to dashboard Cite

Health Canada recently approved the use of varenicline as a pharmacotherapy for smoking cessation. Varenicline works by stimulating dopamine, which results in reduced cravings and withdrawal symptoms. The drug also blocks nicotine receptors, which prevents the dopamine release associated with nicotine consumption. 1The drug has been examined in a few small randomized controlled trials.2-5 Despite limited evidence concerning its use, varenicline is viewed by many clinicians and researchers as the most effective smoking cessation aid. Consequently, there is a need for a systematic assessment of the effectiveness of varenicline relative to placebo. Furthermore, there is a need to compare the efficacy of varenicline with that of existing pharmacotherapies, including sustained-release bupropion and approved nicotine replacement therapies.We undertook a meta-analysis of placebo-controlled randomized controlled trials of the efficacy of 7 pharmacotherapies approved for smoking cessation. We had 3 objectives: to summarize the efficacy of each pharmacotherapy; to undertake a direct comparison of varenicline and bupropion by analyzing trials that contained both varenicline and bupropion treatment arms; and to undertake an indirect comparison of all 7 pharmacotherapies using the results of the individual trials.

show abstract

“…The major disadvantage is nicotine underdosing. In three placebo-controlled trials the inhaler doubled the 1-yr success rate (15,15 and 34% in active groups) [10,13].…”

mentioning

confidence: 98%

Smoking cessation with four nicotine replacement regimes in a lung clinic

Tønnesen¹,

Mikkelsen²

2000

Eur Respir J

View full text Add to dashboard Cite

Smoking cessation with four nicotine replacement regimes in a lung clinic. P. Tùnnesen, K.L. Mikkelsen. #ERS Journals Ltd 2000. ABSTRACT: Smoking cessation is a key intervention for prevention of several lung diseases. The aim of the present study was to compare the effect of smoking cessation with nicotine replacement in a lung clinic in a low resource set-up suitable for implementation in other lung clinics.This was an open, randomized trial with 4 different nicotine replacement regimes combined with minimal behavioural support in daily routine. A total of 446 smokers (>9 cigarettes . day ) were allocated to a nurse-conducted smoking cessation programme with 4 treatment arms: a 5-mg nicotine patch ("placebo"), a 15-mg nicotine patch, nicotine inhaler, and a 15-mg nicotine patch plus nicotine inhaler. Recommended use of the nicotine products were 3 months with the possibility of continuing use up to 9 months on an individual basis. Individual follow-up studies were scheduled after 2 and 6 weeks, 3, 6, 9 and 12 months.The 12-month point prevalence was 6% (5-mg patch (placebo)), 16% (15-mg patch) (p<0.05), 9% (inhaler) and 11% (15-mg patch plus inhaler), respectively.To conclude, the set-up investigated in this study which included minimal behavioural support with nicotine patches should be evaluated in other lung clinics, as it doubled success rate when compared to a placebo with a 1-yr point prevalence of 16% and also the resources used are limited. Eur Respir J 2000; 16: 717±722.

show abstract

Combined Use of Nicotine Patch and Gum in Smoking Cessation: A Placebo-Controlled Clinical Trial

Cited by 216 publications

References 0 publications

Time-Varying Processes Involved in Smoking Lapse in a Randomized Trial of Smoking Cessation Therapies

Time-Varying Processes Involved in Smoking Lapse in a Randomized Trial of Smoking Cessation Therapies

Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials

Smoking cessation with four nicotine replacement regimes in a lung clinic

Contact Info

Product

Resources

About